

**Amendments to the Claims:**

**Claims 1-22 (Cancelled)**

23. **(Currently Amended)** A cell having a transferred fusion protein, said fusion protein transferred by:  
\_\_\_\_\_ coating the surface of said cell with a first protein, wherein said first protein is a lipidated protein; and  
\_\_\_\_\_ contacting said cell with a second protein, wherein said second protein is said fusion protein and is comprised of a first domain having affinity for said first protein and a second domain having *trans* signaling and/or adhesion function having a lipidated protein incorporated into the cell membrane, said lipidated protein having bound thereto a fusion protein, said fusion protein comprising a first domain and a second domain, said second domain having a *trans* signaling and/or adhesion function.

**Claims 24-36 (Withdrawn)**

**Claims 37-50 (Cancelled)**

51. **(Currently Amended)** The cell of Claim 23, wherein said first lipidated protein is selected from the group consisting of lipidated protein A and lipidated protein G.

52. **(Currently Amended)** The cell of Claim 23, wherein said first lipidated protein is palmitated protein A.

53. **(Currently Amended)** The cell of Claim 23, wherein said first domain is attached at the amino terminus of said second fusion protein.

54. **(Currently Amended)** The cell of Claim 23, wherein said first domain is attached at the carboxyl terminus of said second fusion protein.

55. **(Previously added)** The cell of Claim 23, wherein said second domain encodes a type I membrane protein.

56. **(Previously added)** The cell of Claim 23, wherein said second domain encodes a type II membrane protein.

57. **(Previously added)** The cell of Claim 23, wherein said second domain encodes a costimulator.

58. **(Previously added)** The cell of Claim 23, wherein said second domain encodes an inhibitor.

59. **(Previously added)** The cell of Claim 57, wherein said costimulator is selected from the group consisting of B7-1, B7-2, ICAM-1, ICAM-2, ICAM-3, CD48, LFA-3, 4-1BB ligand, CD30 ligand, CD40 ligand, and heat stable antigen.

60. **(Currently Amended)** The cell of Claim 59, wherein said second fusion protein is B7-1-Fc $\gamma$ <sub>1</sub>.

61. **(Previously added)** The cell of Claim 58, wherein said inhibitor is selected from the group consisting of CD8, Fas ligand and a single chain Fv derivative of immunoglobulin.